Alnylam Pharmaceuticals, Inc. (ALNY) Coverage Initiated at Nomura
Equities research analysts at Nomura began coverage on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research report issued on Thursday, The Fly reports. The brokerage set a “reduce” rating and a $56.00 price target on the biopharmaceutical company’s stock. Nomura’s price objective would suggest a potential downside of 28.39% from the company’s previous close.
A number of other research analysts also recently issued reports on ALNY. Chardan Capital reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday. Stifel Nicolaus reiterated a “buy” rating and issued a $56.00 price target (up from $47.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, August 10th. Leerink Swann reiterated a “market perform” rating and issued a $72.00 price target (down from $83.00) on shares of Alnylam Pharmaceuticals in a report on Friday, September 8th. They noted that the move was a valuation call. Morgan Stanley lifted their price target on Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the company an “equal weight” rating in a report on Thursday, August 10th. Finally, Barclays PLC lifted their price target on Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $82.25.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 2.94% during midday trading on Thursday, reaching $78.20. The company had a trading volume of 683,025 shares. Alnylam Pharmaceuticals has a 1-year low of $31.38 and a 1-year high of $89.45. The stock’s market capitalization is $7.17 billion. The firm’s 50 day moving average price is $81.65 and its 200-day moving average price is $68.34.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). The firm had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The company’s revenue for the quarter was up 82.9% on a year-over-year basis. During the same period last year, the firm earned ($1.05) earnings per share. Equities research analysts expect that Alnylam Pharmaceuticals will post ($5.18) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Coverage Initiated at Nomura” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/09/14/alnylam-pharmaceuticals-inc-alny-coverage-initiated-at-nomura.html.
A number of institutional investors have recently bought and sold shares of ALNY. BlackRock Inc. grew its stake in Alnylam Pharmaceuticals by 34,755.2% during the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after purchasing an additional 4,732,617 shares during the last quarter. Perceptive Advisors LLC grew its stake in Alnylam Pharmaceuticals by 831.4% during the 1st quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock valued at $56,553,000 after purchasing an additional 985,000 shares during the last quarter. FMR LLC grew its stake in Alnylam Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after purchasing an additional 815,270 shares during the last quarter. Vanguard Group Inc. grew its stake in Alnylam Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after purchasing an additional 759,295 shares during the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at about $53,226,000. Institutional investors and hedge funds own 94.27% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.